BioPharma Solutions
NGS-based detection and discovery solutions for Biopharma, CRO and Drug discovery research fields
Overview
NGS solution specialized for Biopharma/CRO/Drug discovery research fields
Celemics offers an NGS-based development and commercialization service for biopharma companies. With our proprietary technologies, this will enable comprehensive and adequate genomic profiling test, such as stratification of patient cohorts, patient screening for clinical trials, marker discovery, and other researches related to drug development, thereby enhancing the efficiency of NGS solution in diverse parts in biopharma-related sphere.
Features & Benefits
End-to-End Support from Pilot Trials to Full-Scale Commercialization
Our support for biopharma partners expedites the commercialization process. We help our partners to meet the quality system requirements and country-specific regulations. Our products are tested through our rigorous in-house validation system, and provided to our partners to better ensure the quality of our products and meet their goals and needs.
Quality guaranteed with proof of documentation
As quality control and lot control plays crucial role in successful and accurate clinical research and diagnostics, Celemics keep detailed records of all produced and manufactured products.
From kits to bioinformatics, we keep track record of documentation for our lot-control and quality-control processes.
We can provide our customers documentation guaranteeing the expiry date of our products, supporting our customers to conduct best practice in their research and diagnostics journey.
Composed of commonly tested targets associated with cancer
Celemics’ cancer panels are composed of mutual targets that are commonly known to be associated with cancer. With our exclusive technology for designing probes and panels, you will experience proven performance that detects all kinds of variants, including SNV, CNV, InDel and even for novel variant discovery.
CancerScreen Biomarkers and FDA-Approved Anticancer Agents
CancerScreen 50 Panel | CancerScreen Core Panel | Biomarkers | FDA-approved anticancer agents targeting the corresponding gene |
|---|---|---|---|
| ALK (Fusion) | Crizotinib, Ceritinib, Alectinib, Lorlatinib | ||
| BRAF | Dabrafenib+Trametinib, Vemurafenib+Cobimetinib, Encorafenib+Binimetinib | ||
| EGFR | Gefitinib, Erlotinib, Afatinib, Osimertinib | ||
| ERBB2 | Trastuzumab, Pertuzumab, Ado-trastuzumab, Emtansine, Neratinib | ||
| KRAS | Sotorasib , Cetuximab, Panitumumab | ||
| MET | Crizotinib | ||
| NRAS | Cetuximab, Panitumumab | ||
| PIK3CA | Alpelisib, Copanlisib, Duvelisib | ||
| RET (Fusion) | Cabozantinib, Vandetanib, LOXO-292, BLU-667 | ||
| ROS1 (Fusion) | Crizotinib, Ceritinib, Entrectinib | ||
| FGFR3 | Erdafitinib | ||
| IDH1/2 | Ivosidenib, Enasidenib | ||
| NTRK1 (Fusion) | Larotrectinib, Entrectinib | ||
| PDGFRA | Imatinib | ||
Flexible Panel Customization
A flexible customization service where additional genes of interest can be added to the Ready-to-Use panels, or a customized panel is newly designed and manufactured. Prior to designing the panel, our experienced researchers and technicians engage in interactive discussion with customers especially over difficult regions such as GC-rich or homologous regions that other companies often fail to capture.
Ready-to-Use Panels
| Specification | CancerScreen Core Panel | CancerScreen 50 Panel |
|---|---|---|
| Gene Count | 13 genes | 54 genes |
| Genes | APC, BRAF, EGFR, ERBB2, KRAS, MET, NRAS, PIK3CA, SMAD4, TP53 Fusion : ALK, RET, ROS1 | ABL1, AKT1, ALK, APC, ATM, BRAF, BRCA1, BRCA2, CDH1, CDK4, CDK6, CDKN2A, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB4, ESR1, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, JAK2, KDR, KIT, KRAS, MAP2K1, MET, MLH1, MTOR, MYC, MYCN, NOTCH1, NRAS, NTRK1, PDGFRA, PIK3CA, PTCH1, PTEN, PTPN11, RB1, RET, ROS1, SMAD4, SMO, SRC, STK11, TP53 Fusion : ALK , RET, ROS1, NTRK1 |
| Target size | 61 kb + Rearrangement | 197 kb + Rearrangement |
| Mutation type | SNV, Indel, CNV, Rearrangement | |
| Sample type | FFPE, frozen tissue, cfDNA, RNA | |
| Platform | All sequencers from Illumina, ThermoFisher, MGI, and PacBio | |
| Bioinformatics pipeline | Primary, Secondary, and Tertiary analysis result - FASTQ to VCF, VCF to Clinical report | |
Related Products
Comprehensive NGS panel for identifying and characterizing the molecular fingerprint for solid tumors with market-leading sensitivity
Clinically validated ctDNA panel with exceptional accuracy, even for ultra-low VAF variant detection
Ultimate exonic coverage; industry-leading capture performance and sequencing efficiency accompanied by complete BI solution
End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis
Comprehensive NGS panel for identifying and characterizing the molecular fingerprint for solid tumors with market-leading sensitivity
Clinically validated ctDNA panel with exceptional accuracy, even for ultra-low VAF variant detection
Ultimate exonic coverage; industry-leading capture performance and sequencing efficiency accompanied by complete BI solution
End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis